Sign in
Taking peopleNo phase

Collecting blood and skin samples from people with primary mitochondrial diseases and healthy volunteers

Collects blood and skin samples from people with mitochondrial diseases and healthy volunteers.

Key facts

Who runs it
Minovia Therapeutics Ltd.
Where
Israel1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Collection of Blood and Skin Samples From Patients With Primary Mitochondrial Diseases and Healthy Volunteers
Status
Recruiting
People taking part
100 people, planned
Started
12 May 2024
Expected to end
30 May 2027
Type of study
Observational
Record updated
1 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with a primary mitochondrial disease, and healthy volunteers, to give blood and skin samples.

Age
3 to 85 years
Sex
Male or female
Disease stage
Patients need a clinical diagnosis of primary mitochondrial disease confirmed by mtDNA sequencing. Healthy volunteers need normal vital signs and BMI for age, and no active illness.
Earlier treatment
No antibiotic or antiviral medicines and no blood transfusion in the past 2 weeks. Healthy volunteers take no current medicines other than acetaminophen and naproxen sodium. No past donor stem cell transplant or gene therapy.
Biomarker or test result
For patients: the disease must be confirmed by mtDNA sequencing.

Main reasons for not taking part

  • Past allogeneic hematopoietic stem cell transplant (donor blood stem cells) or gene therapy
  • Viral or bacterial illness in the past 2 weeks
  • Pregnant or breastfeeding
  • Alcohol use of 2 or more drinks a day
  • Recreational or illicit drug use, or tobacco or nicotine products, in the past 1 year

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Male or female, age 3 to 85 years
  • For patients with Primary Mitochondrial Disease:; Clinical diagnosis of PMD confirmed by mtDNA sequencing
  • For Healthy Volunteers:; Normal Vital signs and BMI for age; No active medical conditions or diseases; No current medications, other than acetaminophen and naproxen sodium
  • For All Subjects:; No viral or bacterial illness in past 2 weeks; No antibiotic or antiviral medications in past 2 weeks; No blood transfusion in past 2 weeks; No current pregnancy; Not currently breastfeeding; Alcohol use less than 2 drinks / day; No recreational or illicit drug use in previous 1 year; No tobacco or nicotine containing products in previous 1 year
  • Patient, parent or guardian able to understand and provide voluntary written informed consent

Who cannot take part

  • History of prior treatment with allogeneic hematopoietic stem cell transplantation, or gene therapy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 3 and 85 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Mitochondrial diseases are a genetically diverse group of disorders, some of which are caused by mutations or deletions in the mitochondrial DNA (mtDNA) and which display a wide range of severity and phenotypes. Despite a prevalence of roughly 1 in 8500 in the population there is no effective treatments for the majority of mitochondrial diseases beyond supportive care (Gorman 2016, Elliott 2008). Many of these, such as Pearson syndrome and Kearns-Sayre syndrome, are early onset disorders, and may lead to mortality within the first decades of life. Importantly, mitochondria are selectively inherited from the mother. In addition, there are numerous diseases in which mitochondrial dysfunction plays an important role. Some examples are Alzheimer's and Parkinson's disease, both of which are known to have mitochondrial involvement.

Read full original descriptionShow less

Minovia therapeutics develops a therapeutic intervention called mitochondrial augmentation technology (MAT). For the development work, Minovia needs patients' cells with different mutations that will allow to study the baseline heteroplasmy and functionality of patient hematopoietic cells, identify potential biomarkers to assess mitochondrial content and function in liquid biopsies, and study the efficacy of MAT in different PMDs.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Collection of Blood and Skin Samples From Patients With Primary Mitochondrial Diseases and Healthy Volunteers
Plain-language title
Collecting blood and skin samples from people with primary mitochondrial diseases and healthy volunteersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT06474104, who can take part
Record updated
1 October 2025